AS1810722

AS1810722 is an orally active and potent STAT6 inhibitor with an IC 50 of 1.9 nM. AS1810722 shows a good profile of CYP3A4 inhibition. AS1810722, a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research In Vitro AS1810722 (compound 24) inhibits production of IL-4 with an IC 50 of 2.4 nM, but shows no effect on production of IFN-γ. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo AS1810722 (compound 24; 0.03-0.3 mg/kg; orally; 30 min before, and 24h and 48 h after OVA exposure) suppress eosinophil infiltration in the lung in a dose-dependent manner in an antigen-induced mouse asthmatic model . AS1810722 inhibits in vitro Th2 differentiation with an IC 50 of 2.4 nM without affecting type 1 helper T (Th1) cell differentiation and eosinophil infiltration in an antigen-induced mouse asthmatic model after oral administration . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female Balb/c mice asthmatic model by intraperitoneal injection of ovalbumin (OVA)-containing aluminum hydroxide gel Dosage: 0.03-0.3 mg/kg Administration: Orally; 30 min before, and 24 and 48 h after OVA exposure Result: Suppressed eosinophil infiltration in the lung in a dose-dependent manner. Form:Solid IC50& Target:STAT6 1.9 nM (IC 50 ) CYP3A4

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet